Item 8.01 Other Events.
On
The invention which is the subject of the provisional patent application which is the subject of the press release attached to this Current Report as Exhibit 99.1 is intended at expanding the use of the Company's patented technology to inhibit a T cell checkpoint called NR2F6. The Company has multiple patented and patent-pending approaches to treating cancer directly or via immunotherapy. Immunotherapy drugs are ones which manipulate the body's own immune system to clear it of cancer. By releasing the natural brake in T cells, the Company expects that its drugs will allow a patient's immune cells to be highly activated. The Company is pursuing several such approaches within this very competitive field of cancer treatment. Therefore, the Company has a patent portfolio built around cellular therapies, small molecules, aptamers and RNA vaccines.
Item 9.01 Exhibits.
Exhibit No. Description of Exhibit 99.1 Press Release 2
© Edgar Online, source